FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug
INDIANAPOLIS — Federal regulators put off a decision on whether to approve an Eli Lilly Alzheimer’s drug by making an unusual request to have outside advisers look at the treatment. Lilly had expected the Food and Drug Administration to decide on donanemab’s approval by the end of the month. But the drugmaker said Friday that … Read more
